Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against antigens in replication deficient recombinant virus vaccines

Details for Australian Patent Application No. 2010223524 (hide)

Owner Bavarian Nordic A/S

Inventors Brinkmann, Kay; Baur, Karen; Hausmann, Jurgen

Agent Pizzeys

Pub. Number AU-A-2010223524

PCT Pub. Number WO2010/102822

Priority EP09009759 28.07.09 EP; 61/159,857 13.03.09 US

Filing date 11 March 2010

Wipo publication date 16 September 2010

International Classifications

C07K 14/07 (2006.01) Peptides having more than 20 amino acids

A61K 39/285 (2006.01) Medicinal preparations containing antigens or antibodies

C12N 15/863 (2006.01) Mutation or genetic engineering - Poxviral vectors, e.g. vaccinia virus

Event Publications

7 July 2011 PCT application entered the National Phase

  PCT publication WO2010/102822 Priority application(s): WO2010/102822

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010223526-Sodium salt of 5-cyclopropyl-2-{[2-(2,6difluorophenyl)pyrimidin-5-yl]amino}benz oic acid as DHODH inhibitor

2010223517-Compression casing for a fuel cell stack and a method for manufacturing a compression casing for a fuel cell stack